The impact of eculizumab on routine complement assays-Reference-Cited by-同舟云学术

The impact of eculizumab on routine complement assays

Published:2018-09 Issue: Volume:460 Page:63-71
ISSN:0022-1759
Container-title:Journal of Immunological Methods
language:en
Short-container-title:Journal of Immunological Methods

Author:

Willrich Maria A.V.,Andreguetto Bruna D.,Sridharan Meera^ORCID,Fervenza Fernando C.,Tostrud Linda J.,Ladwig Paula M.,Rivard Ann M.,Hetrick MeLea D.,Olson Ryan N.,Bryant Sandra C.,Snyder Melissa R.,Murray David L.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference25 articles.

1. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases;Ardissino;Am. J. Kidney Dis.,2014

2. In reply to 'discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome';Ardissino;Am. J. Kidney Dis.,2015

3. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update;Ardissino;Am. J. Kidney Dis.,2015

4. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update;Ardissino;Pediatr. Nephrol.,2018

5. Eculizumab for dense deposit disease and C3 glomerulonephritis;Bomback;Clin. J. Am. Soc. Nephrol.,2012

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics;British Journal of Clinical Pharmacology;2024-02-19

2. The safety and efficacy profile of eculizumab in myasthenic crisis: a prospective small case series;Therapeutic Advances in Neurological Disorders;2024-01

3. Modeling complement activation on human glomerular microvascular endothelial cells;Frontiers in Immunology;2023-10-25

4. Atypical haemolytic uremic syndrome with refractory multiorgan involvement and heterozygous CFHR1/CFHR3 gene deletion;BMC Nephrology;2023-05-05

5. Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future;Pediatric Drugs;2023-01-13